Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen

Circulation

Volumn 115, Issue 25, 2007, Pages 3197-3204

  Satoh, Minoru ^a   Matter, Christian M ^b,c   Ogita, Hisakazu ^a   Takeshita, Kyosuke ^a   Wang, Chao Yung ^a   Dorn II, Gerald W ^d   Liao, James K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Antioxidants; Apoptosis; Heart failure; Hormones

Indexed keywords

ANGIOTENSIN II; ANTIESTROGEN; APOPTOSIS SIGNAL REGULATING KINASE 1; AZELAIC ACID; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE P38; PLACEBO; RAC1 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE; THIOREDOXIN; THIOREDOXIN REDUCTASE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; TRANSGENIC MOUSE;

ACETOPHENONES; ANGIOTENSIN II; ANIMALS; APOPTOSIS; CARDIOMYOPATHY, DILATED; CELL SIZE; CYTOSOL; DICARBOXYLIC ACIDS; DRUG IMPLANTS; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HEART FAILURE, CONGESTIVE; HYDROGEN PEROXIDE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MAP KINASE KINASE KINASE 5; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; MITOCHONDRIA; MYOCYTES, CARDIAC; NADPH OXIDASE; NEUROPEPTIDES; OXIDATION-REDUCTION; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAC GTP-BINDING PROTEINS; RATS; SUPEROXIDES; THIOREDOXIN; THIOREDOXIN REDUCTASE (NADPH);

EID: 34347361680     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.657981     Document Type: Article

References (41)

1. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.
2. Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation. 2002;105:1368-1373.
3. Morey AK, Pedram A, Razandi M, Prins BA, Hu RM, Biesiada E, Levin ER. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology. 1997;138:3330-3339.
4. Nascimento CA, Kauser K, Rubanyi GM. Effect of 17beta-estradiol in hypercholesterolemic rabbits with severe endothelial dysfunction. Am J Physiol. 1999;276:H1788-H1794.
5. van Eickels M, Grohe C, Cleutjens JP, Janssen BJ, Wellens HJ, Doevendans PA. 17beta-Estradiol attenuates the development of pressure-overload hypertrophy. Circulation. 2001;104:1419-1423.
6. Maack C, Kartes T, Kilter H, Schafers HJ, Nickenig G, Bohm M, Laufs U. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation. 2003;108:1567-1574.
7. Dieterich S, Bieligk U, Beulich K, Hasenfuss G, Prestle J. Gene expression of antioxidative enzymes in the human heart: increased expression of catalase in the end-stage failing heart. Circulation. 2000;101:33-39.
8. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura K, Egashira K, Takeshita A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res. 1999;85:357-363.
9. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol. 2003;41:2164-2171.
10. Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, Liao JK. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A. 2006;103:7432-7437.
11. Byrne JA, Grieve DJ, Cave AC, Shah AM. Oxidative stress and heart failure. Arch Mal Coeur Vaiss. 2003;96:214-221.
12. Sudoh N, Toba K, Akishita M, Ako J, Hashimoto M, Iijima K, Kim S, Liang YQ, Ohike Y, Watanabe T, Yamazaki I, Yoshizumi M, Eto M, Ouchi Y. Estrogen prevents oxidative stress-induced endothelial cell apoptosis in rats. Circulation. 2001;103:724-729.
13. Behl C, Skutella T, Lezoualc'h F, Post A, Widmann M, Newton CJ, Holsboer F. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol. 1997;51:535-541.
14. Nordberg J, Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med. 2001;31:1287-1312.
15. Deroo BJ, Hewitt SC, Peddada SD, Korach KS. Estradiol regulates the thioredoxin antioxidant system in the mouse uterus. Endocrinology. 2004;145:5485-5492.
16. Ejima K, Nanri H, Araki M, Uchida K, Kashimura M, Ikeda M. 17beta-Estradiol induces protein thiol/disulfide oxidoreductases and protects cultured bovine aortic endothelial cells from oxidative stress. Eur J Endocrinol. 1999;140:608-613.
17. D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB, Dorn GW II. Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A. 1997;94:8121-8126.
18. Rikitake Y, Oyama N, Wang CY, Noma K, Satoh M, Kim HH, Liao JK. Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1 +/- haploinsufficient mice. Circulation. 2005;112:2959-2965.
19. Nakagami H, Takemoto M, Liao JK. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol. 2003;35:851-859.
20. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, Lazzarino G, Paolocci N, Gabrielson KL, Wang Y, Kass DA. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest. 2005;115:1221-1231.
21. Patten RD, Pourati I, Aronovitz MJ, Baur J, Celestin F, Chen X, Michael A, Haq S, Nuedling S, Grohe C, Force T, Mendelsohn ME, Karas RH. 17beta-Estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res. 2004;95:692-699.
22. Kai H, Mori T, Tokuda K, Takayama N, Tahara N, Takemiya K, Kudo H, Sugi Y, Fukui D, Yasukawa H, Kuwahara F, Imaizumi T. Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. Hypertens Res. 2006;29:711-718.
23. Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res. 2006;71:208-215.
24. Marian AJ, Senthil V, Chen SN, Lombardi R. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol. 2006;47:827-834.
25. Xu Y, Armstrong SJ, Arenas IA, Pehowich DJ, Davidge ST. Cardioprotection by chronic estrogen or superoxide dismutase mimetic treatment in the aged female rat. Am J Physiol Heart Circ Physiol. 2004;287:H165-H171.
26. Laufs U, Adam O, Strehlow K, Wassmann S, Konkol C, Laufs K, Schmidt W, Bohm M, Nickenig G. Down-regulation of Rac-1 GTPase by estrogen. J Biol Chem. 2003;278:5956-5962.
27. Strehlow K, Rotter S, Wassmann S, Adam O, Grohe C, Laufs K, Bohm M, Nickenig G. Modulation of antioxidant enzyme expression and function by estrogen. Circ Res. 2003;93:170-177.
28. Kumar D, Lou H, Singal PK. Oxidative stress and apoptosis in heart dysfunction. Herz. 2002;27:662-668.
29. Narula J, Kolodgie FD, Virmani R. Apoptosis and cardiomyopathy. Curr Opin Cardiol. 2000;15:183-188.
30. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC, Anversa P. Apoptosis in the failing human heart. N Engl J Med. 1997;336:1131-1141.
31. Pelzer T, Schumann M, Neumann M, deJager T, Stimpel M, Serfling E, Neyses L. 17beta-Estradiol prevents programmed cell death in cardiac myocytes. Biochem Biophys Res Commun. 2000;268:192-200.
32. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905-2927.
33. Yamamoto M, Yang G, Hong C, Liu J, Holle E, Yu X, Wagner T, Vatner SF, Sadoshima J. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest. 2003;112:1395-1406.
34. Shioji K, Kishimoto C, Nakamura H, Masutani H, Yuan Z, Oka S, Yodoi J. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation. 2002;106:1403-1409.
35. O'Lone R, Frith MC, Karlsson EK, Hansen U. Genomic targets of nuclear estrogen receptors. Mol Endocrinol. 2004;18:1859-1875.
36. Liu Y, Min W. Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res. 2002;90:1259-1266.
37. Liu H, Nishitoh H, Ichijo H, Kyriakis JM. Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin. Mol Cell Biol. 2000;20:2198-2208.
38. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K, Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 1997;275:90-94.
39. Geisler JG, Zawalich W, Zawalich K, Lakey JR, Stukenbrok H, Milici AJ, Soeller WC. Estrogen can prevent or reverse obesity and diabetes in mice expressing human islet amyloid polypeptide. Diabetes. 2002;51:2158-2169.
40. Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, Chien KR, Brown JH, Dorn GW II. Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A. 1998;95:10140-10145.
41. Beer S, Reincke M, Kral M, Callies F, Stromer H, Dienesch C, Steinhauer S, Ertl G, Allolio B, Neubauer S. High-dose 17beta-estradiol treatment prevents development of heart failure post-myocardial infarction in the rat. Basic Res Cardiol. 2007;102:9-18.